In the latest session, Denali Therapeutics Inc. (NASDAQ: DNLI) closed at $23.82 up 1.06% from its previous closing price of $23.57. In other words, the price has increased by $+0.25 from its previous closing price. On the day, 746435 shares were traded. DNLI stock price reached its highest trading level at $24.26 during the session, while it also had its lowest trading level at $22.94.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
For a deeper understanding of Denali Therapeutics Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.80 and its Current Ratio is at 3.80. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, SVB Securities on January 30, 2023, initiated with a Outperform rating and assigned the stock a target price of $50.
BTIG Research Upgraded its Neutral to Buy on November 02, 2022, while the target price for the stock was maintained at $38.
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 15 when Ho Carole sold 1,476 shares for $29.40 per share. The transaction valued at 43,394 led to the insider holds 182,809 shares of the business.
Watts Ryan J. sold 33,815 shares of DNLI for $1,017,243 on Feb 13. The President and CEO now owns 2,239,913 shares after completing the transaction at $30.08 per share. On Feb 13, another insider, Schuth Alexander O., who serves as the COFO and Secretary of the company, sold 3,497 shares for $30.09 each. As a result, the insider received 105,225 and left with 528,691 shares of the company.
For the stock, the TTM Price-to-Sale (P/S) ratio is 31.19 while its Price-to-Book (P/B) ratio in mrq is 3.04.
Stock Price History:
Over the past 52 weeks, DNLI has reached a high of $39.43, while it has fallen to a 52-week low of $20.24. The 50-Day Moving Average of the stock is 28.61, while the 200-Day Moving Average is calculated to be 29.87.
For the past three months, DNLI has traded an average of 698.90K shares per day and 818.07k over the past ten days. A total of 132.96M shares are outstanding, with a floating share count of 115.72M. Insiders hold about 1.80% of the company’s shares, while institutions hold 69.40% stake in the company. Shares short for DNLI as of Jan 30, 2023 were 7.4M with a Short Ratio of 7.03M, compared to 7.41M on Dec 29, 2022. Therefore, it implies a Short% of Shares Outstanding of 5.45% and a Short% of Float of 7.74%.
There are 15 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.79 for the current quarter, with a high estimate of -$0.41 and a low estimate of -$0.98, while EPS last year was -$0.62. The consensus estimate for the next quarter is -$0.73, with high estimates of -$0.68 and low estimates of -$0.78.
Analysts are recommending an EPS of between -$2.24 and -$2.9 for the fiscal current year, implying an average EPS of -$2.62. EPS for the following year is -$3, with 17 analysts recommending between -$2.34 and -$3.76.
For the next quarter, 8 analysts are estimating revenue of $19.56M, a decrease of -53.60% less than the figure of $4.80% in the same quarter last year. There is a high estimate of $35M for the next quarter, whereas the lowest estimate is $5M.
A total of 16 analysts have provided revenue estimates for DNLI’s current fiscal year. The highest revenue estimate was $151M, while the lowest revenue estimate was $98.18M, resulting in an average revenue estimate of $109.61M. In the same quarter a year ago, actual revenue was $48.66M, up 125.30% from the average estimate. Based on 16 analysts’ estimates, the company’s revenue will be $92.8M in the next fiscal year. The high estimate is $150M and the low estimate is $33.4M. The average revenue growth estimate for next year is down -15.30% from the average revenue estimate for this year.